Therapeutic Solutions International (TSOI) 10-K 16 Jun 16 2014 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2014	Jun. 07, 2016	Jun. 30, 2014
Document and Entity Information:
Entity Registrant Name	THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.
Document Type	10-K
Document Period End Date	Dec. 31, 2014
Trading Symbol	tsoi
Amendment Flag	false
Entity Central Index Key	1,419,051
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		681,951,000
Entity Public Float			$ 1,213,989
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2,014
Document Fiscal Period Focus	FY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 2,894	$ 12,513
Prepaid expenses and other current assets	139,016	68,569
Assets from discontinued operations	46,845	48,189
Total current assets	188,756	129,270
Other non-current assets	12,461	12,441
Property and equipment, net	0	69,133
Total assets	201,217	210,844
Current liabilities:
Accounts payable	290,554	298,521
Accrued expenses and other current liabilities	14,777	251,354
Due to related parties	27,174	236,324
Total current liabilities	332,505	786,199
Shareholders' Equity
Preferred stock, $.001 par value; 5,000,000 shares authorized	0	0
Common stock, $.001 par value; 699,999,999 shares authorized, 400,000,000 issued and outstanding at December 31, 2014 and 699,999,999 shares authorized, 94,466,400 issued and outstanding at December 31, 2013	400,000	94,466
Capital in excess of par	2,233,009	1,665,725
Deficit accumulated	(2,624,296)	(2,335,546)
Total shareholders' equity	(131,288)	(575,355)
Total liabilities and shareholders' equity	$ 201,217	$ 210,844

Consolidated Balance Sheets Par

Consolidated Balance Sheets Parentheticals - $ / shares	Dec. 31, 2014	Dec. 31, 2013
Parentheticals
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	5,000,000	5,000,000
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	699,999,999	699,999,999
Common Stock, shares issued	400,000,000	94,466,400
Common Stock, shares outstanding	400,000,000	94,466,400

Consolidated Statements of Oper

Consolidated Statements of Operations (Audited) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Operating expenses:
General and administrative	$ 50,868	$ 68,932
Salaries, wages, and related costs	111,986	520,933
Amortization and depreciation	21,133	23,320
Consulting fees	39,734	85,515
Legal and professional fees	103,384	149,663
Total operating expenses	327,105	848,364
Loss from operations	(327,105)	(848,364)
Other income (expense):
Net other income (expense)	8,728	22,766
Impairment of intangible asset	(210,000)	0
Interest expense	(9,375)	(10,147)
Total other income (expense)	(210,647)	12,618
Net income (loss) from continuing operations	(537,752)	(835,746)
Net income from discontinued operations	249,002	284,088
Net income (loss)	$ (288,750)	$ (551,658)
Basic and diluted loss per common share
Continuing operation	$ 0	$ (0.01)
Discontinued operation.	$ 0	$ 0
Weighted average shares outstanding	196,385,920	86,534,071

Condensed Consolidated Statemen

Condensed Consolidated Statement of Changes in Shareholders' (Deficit) - USD ($)	Common Stock	Common Stock Amount	Additional Paid-in Capital	Earnings (Deficit) Accumulated	Total
Balance at Dec. 31, 2012	305,458,333	305,458	1,285,533	(1,783,888)	(192,897)
Stock returned & cancelled due to MDRA on January 17, 2013	(223,991,933)	(223,992)	223,992	0	0
Stock issued for service on May 8, 2013	2,000,000	2,000	28,200	0	30,200
Stock options granted June 29, 2013		$ 0	$ 78,000	$ 0	$ 78,000
Stock issued for service on July 10, 2013	2,000,000	2,000	10,000	0	12,000
Stock issued for service on July 15, 2013	4,000,000	4,000	20,000	0	24,000
Stock issued for service on December 2, 2013	5,000,000	5,000	20,000	0	25,000
Net Loss, December 31, 2013		$ 0	$ 0	$ (551,658)	$ (551,658)
Balance at Dec. 31, 2013	94,466,400	94,466	1,665,725	(2,335,546)	(575,355)
Stock issued for service on March 31, 2014	12,000,000	12,000	33,750	0	45,750
Stock issued for note conversion on June 30, 2014	90,000,000	90,000	180,000	0	270,000
Stock issued for note conversion on September 30, 2014	103,533,600	103,534	103,534	0	207,067
Stock issued for a material definitive agreement	100,000,000	100,000	110,000	0	210,000
Net Loss, December 31, 2014		$ 0	$ 0	$ (288,750)	$ (288,750)
Balance at Dec. 31, 2014	400,000,000	400,000	2,093,009	(2,624,296)	(131,288)

Consolidated Statement of Cash

Consolidated Statement of Cash Flows (Audited) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities
Net loss	$ (288,750)	$ (551,658)
Non-cash expenses:
Depreciation	21,132	23,320
Stock based compensation to consultants	45,750	95,200
Compensation expense - employee stock option plan	0	74,000
Imparment of intangible asset	210,000	0
Gain from disposal of property and equipment	(7,000)	0
Changes in operating assets and liabilities:
(Increase) decrease in prepaid expenses and other current assets	(70,447)	(54,034)
(Increase) decrease in other assets	(20)	(31)
Increase (decrease) in accounts payable	(7,967)	116,577
Increase (decrease) in accrued expenses and other current liabilities	(236,577)	226,540
Increase (decrease) in other related party liabilities	272,917	98,083
Cash used by operating activities-continuing operations	(60,962)	27,997
Cash used by operating activities-discontinued operations	1,343	(49,883)
Net cash provided by operating activities	(59,619)	(21,884)
Cash flows from investing activities
Disposal of fixed assets from discontinued operations	55,000	0
Net cash used by by investing activities	55,000	0
Cash flows from financing activities
Borrowing and other advances	0	36,002
Repayments of due to related parties	(5,000)	(36,616)
Net cash provided by financing activities	(5,000)	(614)
Increase in cash	(9,619)	(22,498)
Cash at beginning of period	12,513	35,011
Cash at end of period	2,894	12,513
Significant non-cash investing and financing activities:
Stock issuance for acquisition of intangible assets.	210,000	0
Stock issuance for due to realted parties	477,067	0
Supplemental Cash Flow Information:
Cash paid for interest	2,812	2,956
Cash paid for income taxes	$ 800	$ 800

Nature of Business

Nature of Business	12 Months Ended
	Dec. 31, 2014
Nature of Business:
Nature of Business	Note 1 – Nature of Business Therapeutic Solutions International, Inc. (the “Company”) was organized August 6, 2007 under the name Friendly Auto Dealers, Inc., under the laws of the State of Nevada. In the first quarter of 2011 the Company changed its name from Friendly Auto Dealers, Inc. to Therapeutic Solutions International, Inc., and acquired Splint Decisions, Inc., a California corporation organized September 21, 2010 (“Splint”). Splint is treated as the “accounting acquirer” in the accompanying financial statements. Until April 28, 2014 the Company sold (directly and through distributors and sublicensees), in non-US countries, plastic intraoral devices known as Anterior Midpoint Stop Appliances (“AMPSA Products”) . On April 28, 2014, we received a letter from Mr. J. Christopher Jaczko, a lawyer with the Procopio law firm in San Diego who represents Boyd Research, Inc. and related parties. In his letter, Mr. Jaczko notified us that our license to use the international patents for our AMPSA device, pursuant to our license agreement with his clients effective January 1, 2013, was terminated. The ostensible reason Mr. Jaczko gave was our failure to make certain unspecified payments due under the license agreement to his clients. We disputed the termination, but believed that the costs involved with litigating the termination of the New License was not in the best interest of the Company and its shareholders. Therefore, the Company moved in a new direction. Currently the Company is involved in the medical sciences market. We are focused on three different areas within the same market. They are outlined as follows: · Dietary Supplements · Immunotherapy, and · Fetal - Maternal Health

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Significant Accounting Policies:
Significant Accounting Policies	Note 2 – Significant Accounting Policies Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash For the Statements of Cash Flows, all highly liquid investments with maturity of three months or less are considered to be cash equivalents. There were no cash equivalents as of December 31, 2014 and 2013. Other assets include restricted cash of $10,000 that is used to secure a company credit card. Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutrasecutal formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. During the year ended December 31, 2014, the Company recognized an impairment charge of $210,000 for intangible assets. Income Taxes The Company accounts for income taxes under ASC 740 "Income Taxes," "Accounting for Income Taxes" “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” Going Concern The Company's financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has experienced recurring losses over the past years which have resulted in stockholders’ accumulated deficits of approximately $2,624 thousand at December 31 2014. These conditions raise uncertainty about the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is contingent upon its ability to secure additional financing, increase sales of its products and attain profitable operations. It is the intent of management to continue to raise additional capital. However, there can be no assurance that the Company will be able to secure such additional funds or obtain such on terms satisfactory to the Company, if at all. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Share Based Expenses ASC 718 "Compensation - Stock Compensation," The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50 "Equity-Based Payments to Non-Employees," "Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring or in Conjunction with Selling, Goods or Services". Recently Implemented Standards The Company has implemented all new accounting pronouncements that are in effect that may impact its financial statements and does not believe that there are any new accounting pronouncements that have been issued that might have a material impact on its financial statements.

Restricted Cash

Restricted Cash	12 Months Ended
	Dec. 31, 2014
Restricted Cash:
Restricted Cash	Note 3 – Restricted Cash Other non-current asset is a $10,000 certificate of deposit with an annual interest rate of 0.6%. This certificate matures on June 17, 2016, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011.

Equipment

Equipment	12 Months Ended
	Dec. 31, 2014
Equipment
Equipment	Note 4 – Equipment The cost and accumulated depreciation of fixed assets and equipment at December 31, 2014 and 2013 are summarized below: December 31, 2014 December 31, 2013 Computer Hardware $ 10,747 $ 10,747 Office Furniture and Equipment 3,639 3,639 Shipping and Other Equipment 1,575 1,575 Molding Equipment Interests - 90,000 Total 15,961 105,961 Accumulated Depreciation (15,961) (36,828) Property and Equipment, net $ - $ 69,133 Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Depreciation expenses for the years ended December 31, 2014 and 2013 were $21,133 and $23,320, respectively.

License Agreements

License Agreements	12 Months Ended
	Dec. 31, 2014
License Agreements:
License Agreements	Note 5 – License Agreements The Company had a New License Agreement for the period from August 24, 2012 to December 31, 2012, an exclusive worldwide license with a 30% royalty on net sales (subject to reduction under certain conditions). Also, the New License Agreement granted the Company, for the period from January 1, 2013 forward, a royalty-free nonexclusive worldwide license to make and sell certain products, but excluding the United States market. On April 28, 2014, the Company received a letter from Mr. J. Christopher Jaczko, a lawyer with the Procopio law firm in San Diego who represents Boyd Research, Inc. and related parties. In his letter, Mr. Jaczko notified us that our license to use the international patents for our AMPSA device, pursuant to our license agreement with his clients effective January 1, 2013, was terminated

Intangible Asset

Intangible Asset	12 Months Ended
	Dec. 31, 2014
Intangible Asset:
Intangible Asset	Note 6 - Intangible Asset On December 9, 2014 the Company contractually obtained the rights, title and interest in and to proprietary formulations for two nutritional supplement products known under the trade names: (a) “T-Rx”; and, (b) “Vital Female; and, (ii) the purchase of all legal right, title and interest, in and to intellectual property including, but not limited to, Innovative’s nutritional supplement product known under the trade name: “Projuvenol.” The Company issued 100,000,000 shares for this rights, title and interest. The fair value of the 100,000,000 shares of common stock of $210,000 has been recorded as intangible assets. On December 31, 2014, the Company performed an impairment test on the intellectual property. The Company recorded impairment of $210,000.

Equity Transactions

Equity Transactions	12 Months Ended
	Dec. 31, 2014
Equity Transactions
Equity Transactions	Note 7 – Equity Transactions Preferred Stock The Company is authorized to issue 5,000,000 shares of $.001 par value preferred stock. The Company has not issued any preferred stock. Common Stock The Company is authorized to issue 699,999,999 shares of $.001 par value common stock. All shares have equal voting rights, are non-assessable, and have one vote per share. Voting rights are not cumulative and, therefore, the holders of more than 50% of the common stock could, if they choose to do so, elect all of the directors of the Company. On July 10, 2013, we issued 2,000,000 shares of common stock, valued at $.006 per shares, for legal services. On July 15, 2013, we issued 4,000,000 shares of common stock, valued at $.006 per share, for consulting services. On November 15, 2013, we issued 5,000,000 shares of common stock, valued at $.005 per share, for consulting services. On March 31, 2014, we issued 2,500,000 shares of common stock, valued at $.0035 per share, for consulting services. On March 31, 2014, we issued 2,500,000 shares of common stock, valued at $.004 per share, for consulting services. On March 31, 2014, we issued 2,000,000 shares of common stock, valued at $.0035 per share, for consulting services. On March 31, 2014, we issued 5.000,000 shares of common stock, valued at $.004 per share, for legal services. On June 19, 2014, we issued 45,000,000 shares of common stock, valued at $.003 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On June 19, 2014, we issued 45,000,000 shares of common stock, valued at $.003 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 26,562,500, shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 21,476,435shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 26,562,500 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 21,250,000 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 7,682,165 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On December 9, 2014, we issued 100,000,000 shares of common stock, valued at $.0021 per share, in regard to a Material Definitive Agreement (Form 8-K filed on December 10, 2014). On April 1, 2015, we issued 10,000,000 shares of common stock, valued at $.0025 per share, for consulting services. On April 11, 2015, we issued 20,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On April 11, 2015, we issued 2,000,000 shares of common stock, valued at $.0025 per share, for consulting services. On April 17, 2015, we issued 20,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On June 1, 2015, we issued 3,000,000 shares of common stock, valued at $.0025 per share, for consulting services. On June 1, 2015, we issued 7,000,000 shares of common stock, valued at $.0025 per share, for legal services On June 8, 2015, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On August 31, 2015, we issued 10,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On November 9, 2015, we issued 3,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On November 16, 2015, we issued 2,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On November 17, 2015, we issued 4,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On November 17, 2015, we issued 31,500,000 shares of common stock, valued at $.0025 per share, for consulting services. On November 17, 2015, we issued 20,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On November 30, 2015, we issued 5,000,000 shares of common stock, valued at $.0025 per share, for consulting services. On November 30, 2015, we issued 2,500,000 shares of common stock, valued at $.0025 per share, for legal services. On January 4, 2016, we issued 2,500,000 shares of common stock, valued at $.0025 per share, for consulting services. On January 22, 2016, we issued 2,500,000 shares of common stock, valued at $.0025 per share, for consulting services. On February 1, 2016, we issued 2,500,000 shares of common stock, valued at $.0025 per share, for consulting services. On February 5, 2016, we issued 8,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On February 22, 2016, we issued 5,451,000 shares of common stock, valued at $.003 per share, in regard to a License Agreement (Form 8-K filed on February 25, 2016). On February 26, 2016, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On March 7, 2016, we issued 10,000,000 shares of common stock, valued at $.0025 per share, for consulting services. On March 21, 2016, we issued 100,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On May 2, 2016, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement and 1,000,000 shares of common stock, valued at $.0025 per share, for consulting services. On May 26, 2016, we issued 2,500,000 shares of common stock, valued at $.0066 per share, for consulting services. On May 26, 2016, we issued 2,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On May 31, 2016, we issued 2,500,000 shares of common stock, valued at $.0066 per share, for legal services. Warrants On February 20, 2009, the Company granted certain compensatory warrants. The fair value of each compensatory warrant granted is estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. Expected volatilities are based on volatilities from the Company's traded common stock since February 20, 2009. As of March 31, 2014 all warrants expired and no warrants were exercised. No warrants were granted by the Company in 2013, 2014 or 2015. A summary of these compensatory warrants outstanding at December 31, 2014 and 2013 and changes during the period is presented below: Warrants Shares Weighted- Average Exercise Price Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value Exercisable at December 31, 2013 250,000 $1.00 .25 $ - Granted 0 Exercised 0 Cancelled/Expired 250,000 Exercisable at December 31, 2014 0 $0 0 $ -

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions:
Related Party Transactions	Note 8 – Related Party Transactions On June 19, 2014, we issued 45,000,000 shares of common stock, valued at $.003 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On June 19, 2014, we issued 45,000,000 shares of common stock, valued at $.003 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 26,562,500, shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 21,476,435shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 26,562,500 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 21,250,000 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 7,682,165 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. As of December 31, 2014, the Company has advanced approximately $127,000 to the officers of the company. Additionally the officers of the Company waived their monthly salary accrual from July 1, 2014 to December 31, 2014. The Company accrued officers salary of $20,384 in 2014 ($43,675 in 2013).

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Taxes:
Income Taxes	Note 9 – Income Taxes The Company has net operating losses carried forward of $2,043,048 (2012 – $1,620,213) available to offset taxable income in future years which expire beginning in fiscal 2031. The Company is subject to United States federal and state income taxes at an approximate rate of 45%. The reconciliation of the provision for income taxes at the United States federal statutory rate compared to the Company’s income tax expense as reported is as follows: December 31, 2014 $ December 31, 2013 $ Net loss before income taxes per financial statements (288,750) (551,658) Income tax rate 45% 45% Income tax recovery (123,619) (248,246) Permanent differences 6,318 155,499 Change in valuation allowance 117,301 92,747 Provision for income taxes – – The significant components of deferred income tax assets and liabilities at December 31, 2014 and 2013 are as follows: December 31, 2014 $ December 31, 2013 $ Net operating loss carry-forward 846,397 729,096 Valuation allowance (846,397) (729,096) Net deferred income tax asset – –

Discontinued Operation

Discontinued Operation	12 Months Ended
	Dec. 31, 2014
Discontinued Operation:
Discontinued Operation	Note 10 – Discontinued Operation On April 28, 2014, we received a letter from Mr. J. Christopher Jaczko, a lawyer with the Procopio law firm in San Diego who represents Boyd Research, Inc. and related parties. In his letter, Mr. Jaczko notified us that our license to use the international patents for our AMPSA device, pursuant to our license agreement with his clients effective January 1, 2013, was terminated. The following are the summarized results of discontinued operations for the years ended December 31, 2014 and 2013 and the Balance Sheet as of December 31, 2014 and 2013: For the Year ended December 31, 2014 For the Year ended December 31, 2013 Net revenues from discontinued operations $ 268,892 $ 311,596 Cost of goods sold (26,798) (11,835) Selling expenses (6,525) (11,515) Royalties 13,433 4,158 Other income from discontinued operations $ 249,002 $ 284,088 December 31, 2014 December 31, 2013 Assets Accounts Receivable, net $ 46,845 $ 21,391 Inventories - 26,798 Total assets of discontinued operations $ 46,845 $ 48,189

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events:
Subsequent Events	Note 11 – Subsequent Events On April 1, 2015, we issued 10,000,000 shares of common stock, valued at $.0025 per share, for consulting services. On April 11, 2015, we issued 20,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On April 11, 2015, we issued 2,000,000 shares of common stock, valued at $.0025 per share, for consulting services. On April 17, 2015, we issued 20,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On June 1, 2015, we issued 3,000,000 shares of common stock, valued at $.0025 per share, for consulting services. On June 1, 2015, we issued 7,000,000 shares of common stock, valued at $.0025 per share, for legal services On June 8, 2015, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On August 31, 2015, we issued 10,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On November 9, 2015, we issued 3,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On November 16, 2015, we issued 2,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On November 17, 2015, we issued 4,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On November 17, 2015, we issued 31,500,000 shares of common stock, valued at $.0025 per share, for consulting services. On November 17, 2015, we issued 20,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On November 30, 2015, we issued 5,000,000 shares of common stock, valued at $.0025 per share, for consulting services on November 30, 2015, we issued 2,500,000 shares of common stock, valued at $.0025 per share, for legal services. On January 4, 2016, we issued 2,500,000 shares of common stock, valued at $.0025 per share, for consulting services. On January 22, 2016, we issued 2,500,000 shares of common stock, valued at $.0025 per share, for consulting services. On February 1, 2016, we issued 2,500,000 shares of common stock, valued at $.0025 per share, for consulting services. On February 5, 2016, we issued 8,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On February 22, 2016, we issued 5,451,000 shares of common stock, valued at $.003 per share, in regard to a License Agreement (Form 8-K filed on February 25, 2016). On February 26, 2016, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On March 7, 2016, we issued 10,000,000 shares of common stock, valued at $.0025 per share, for consulting services. On March 21, 2016, we issued 100,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On May 2, 2016, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement and 1,000,000 shares of common stock, valued at $.0025 per share, for consulting services. On May 26, 2016, we issued 2,500,000 shares of common stock, valued at $.0066 per share, for consulting services. On May 26, 2016, we issued 2,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On May 31, 2016, we issued 2,500,000 shares of common stock, valued at $.0066 per share, for legal services. The Company previously reported, on April 29, 2013 a former employee of the Company, Reid Jilek, sued the Company, its two directors and its three officers in San Diego County (California) Superior Court for breach of contract, retaliation, constructive discharge, failure to pay wages, failure to reimburse, conversion and fraudulent inducement. The complaint related to his employment agreement with the Company and his resignation which was effective in January 2013. The trial was held in September 2014. On September 26, 2014 the Court ruled in favor of the Company and against all of Jilek's claims, and ruled that the Company was the prevailing party, and therefore was entitled to recover its attorney’s fees and costs from Jilek. The Company did not prevail in its cross-claims against Jilek. Jilek's claims against the Company’s directors and officers had previously been dismissed. On December 9, 2014 the Company completed sales of its unregistered restricted common shares to Innovative Supplements, Inc., and Robert F. Graham. The Company sold a total of one hundred million (100,000,000) shares of unregistered restricted common stock at par value ($0.001) per share in exchange for (i) an assignment of Seller and Shareholder’s contractual right, title and interest in and to proprietary formulations for two nutritional supplement products known under the trade names: (a) “T-Rx”; and, (b) “Vital Female; and, (ii) the purchase of all legal right, title and interest, in and to intellectual property including, but not limited to, Innovative’s nutritional supplement product known under the trade name: “Projuvenol.” On July 8, 2015, the United States Patent and Trademark Office (the “USPTO”) accepted U.S. Application No. 62/190170 titled “Augmentation of Oncology Immunotherapies by Pterostilbene Containing Compositions”. On July 21, 2015, the United States Patent and Trademark Office (the “USPTO”) accepted U.S. Application No. 62/194990 titled “Prevention of Pregnancy Complications by Probiotic Administration”. On September 02, 2015, the United States Patent and Trademark Office (the “USPTO”) accepted U.S. Application No. 62/213260 titled “Preventative Methods and Therapeutic or Pharmaceutical Compositions for the Treatment or Prevention of Pregnancy Complications”. On September 15, 2015, the United States Patent and Trademark Office (the “USPTO”) accepted U.S. Application No. 62/219020 titled “Diagnostic Methods For The Assessment Of Pregnancy Complications”. On September 25, 2015, the United States Patent and Trademark Office (the “USPTO”) accepted U.S. Application No. 62/232722 titled “A Medical Device For Reducing The Risk Of Preterm-Labor And Preterm-Birth”. On October 20, 2015, OmniBiome, Inc, a wholly owned subsidiary of the Company, was incorporated in the State of Delaware. On October 28, 2015, MolecuVax, Inc, a wholly owned subsidiary of the Company, was incorporated in the State of Delaware. On November 18, 2015, Therapeutic Solutions International, Inc. licensed certain intellectual property to OmniBiome, Inc., a wholly owned subsidiary of Therapeutic Solutions International, Inc., as follows: (1) Application No. 62/213260 titled “Preventative Methods and Therapeutic or Pharmaceutical Compositions for the Treatment or Prevention of Pregnancy Complications” covers utility of vaccines and various agents to alter pathological conditions in which the maternal immune system induces a process of inflammation that culminates in placental alterations leading to either fetal loss or preterm labor; (2) Application No. 62/219020 “Diagnostic Methods For The Assessment Of Pregnancy Complications” a cytokine-based diagnostic kit aimed at stratifying risk of preterm labor and other pregnancy associated complications; and (3) Application No. 62/232722 “A Medical Device For Reducing The Risk Of Preterm-Labor And Preterm-Birth” covering various medical devices aimed at immune modulating the cervical microenvironment in order to prevent preterm labor. On May 2, 2016 we retired to the treasury 62,500,000 common shares of our holdings in MolecuVax, Inc. (MVAX). After this retirement, we currently own 37,500,000 common shares of MVAX. On May 3, 2016 MVAX issued 37,500,000 of its common shares in conjunction with a licensing agreement between MVAX and UNIVAX, LLC to UNIVAX, LLC. On November 20, 2015, the United States Patent and Trademark Office (the “USPTO”) accepted U.S. Application No. 62/258007 titled “Exosome Mediated Innate and Adaptive Immune Stimulation for Treatment of Cancer”. On December 04, 2015, Therapeutic Solutions International, Inc. licensed certain intellectual property to OmniBiome, Inc., a wholly owned subsidiary of Therapeutic Solutions International, Inc., Application No. 62/194990 titled “Prevention of Pregnancy Complications by Probiotic Administration.” On January 21, 2016, our Board of Directors elected Thomas E. Ichim, Ph.D, to fill a vacant seat on our Board of Directors. On February 05, 2016, Therapeutic Solutions International, Inc. licensed certain intellectual property to MolecuVax, Inc., a wholly owned subsidiary of Therapeutic Solutions International, Inc., Application No. 62/258,007 titled “Exosome Mediated Innate and Adaptive Immune Stimulation for Treatment of Cancer.” On April 27, 2016, the United States Patent and Trademark Office (the “USPTO”) accepted U.S. Application No. 62/327756 titled “Augmentation Of Stem Cell Activity Using Pterostilbene And Compositions Containing Pterostilbene”.

Accounting Policies (Policies)

Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies:
Estimates	Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash, Policy	Cash For the Statements of Cash Flows, all highly liquid investments with maturity of three months or less are considered to be cash equivalents. There were no cash equivalents as of December 31, 2014 and 2013. Other assets include restricted cash of $10,000 that is used to secure a company credit card.
Depreciation and Amortization, Policy	Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement.
Intangible Assets, Policy	Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutrasecutal formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.”
Long-lived Assets	Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. During the year ended December 31, 2014, the Company recognized an impairment charge of $210,000 for intangible assets.
Income Taxes, Policy	Income Taxes The Company accounts for income taxes under ASC 740 "Income Taxes," "Accounting for Income Taxes" “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.”
Going Concern	Going Concern The Company's financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has experienced recurring losses over the past years which have resulted in stockholders’ accumulated deficits of approximately $2,624 thousand at December 31 2014. These conditions raise uncertainty about the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is contingent upon its ability to secure additional financing, increase sales of its products and attain profitable operations. It is the intent of management to continue to raise additional capital. However, there can be no assurance that the Company will be able to secure such additional funds or obtain such on terms satisfactory to the Company, if at all. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
Share Based Expenses	Share Based Expenses ASC 718 "Compensation - Stock Compensation," The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50 "Equity-Based Payments to Non-Employees," "Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring or in Conjunction with Selling, Goods or Services".
Recently Implemented Standards	Recently Implemented Standards The Company has implemented all new accounting pronouncements that are in effect that may impact its financial statements and does not believe that there are any new accounting pronouncements that have been issued that might have a material impact on its financial statements.

Schedule of Cost and accumulate

Schedule of Cost and accumulated depreciation of fixed assets and equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Cost and accumulated depreciation of fixed assets and equipment:
Schedule of Cost and accumulated depreciation of fixed assets and equipment	The cost and accumulated depreciation of fixed assets and equipment at December 31, 2014 and 2013 are summarized below: December 31, 2014 December 31, 2013 Computer Hardware $ 10,747 $ 10,747 Office Furniture and Equipment 3,639 3,639 Shipping and Other Equipment 1,575 1,575 Molding Equipment Interests - 90,000 Total 15,961 105,961 Accumulated Depreciation (15,961) (36,828) Property and Equipment, net $ - $ 69,133

Schedule of Summary of compensa

Schedule of Summary of compensatory warrants outstanding (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Summary of compensatory warrants outstanding:
Schedule of Summary of compensatory warrants outstanding	A summary of these compensatory warrants outstanding at December 31, 2014 and 2013 and changes during the period is presented below: Warrants Shares Weighted- Average Exercise Price Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value Exercisable at December 31, 2013 250,000 $1.00 .25 $ - Granted 0 Exercised 0 Cancelled/Expired 250,000 Exercisable at December 31, 2014 0 $0 0 $ -

Schedule of Income Taxes (Table

Schedule of Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Income Taxes (Tables):
Schedule of Effective Income Tax Rate Reconciliation	The Company is subject to United States federal and state income taxes at an approximate rate of 45%. The reconciliation of the provision for income taxes at the United States federal statutory rate compared to the Company’s income tax expense as reported is as follows: December 31, 2014 $ December 31, 2013 $ Net loss before income taxes per financial statements (288,750) (551,658) Income tax rate 45% 45% Income tax recovery (123,619) (248,246) Permanent differences 6,318 155,499 Change in valuation allowance 117,301 92,747 Provision for income taxes – –
Schedule of Deferred Tax Assets and Liabilities	The significant components of deferred income tax assets and liabilities at December 31, 2014 and 2013 are as follows: December 31, 2014 $ December 31, 2013 $ Net operating loss carry-forward 846,397 729,096 Valuation allowance (846,397) (729,096) Net deferred income tax asset – –

Schedule of Summary of Results

Schedule of Summary of Results of Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Summary of Results of Discontinued Operations
Schedule of Summary of Results of Discontinued Operations	The following are the summarized results of discontinued operations for the years ended December 31, 2014 and 2013 and the Balance Sheet as of December 31, 2014 and 2013: For the Year ended December 31, 2014 For the Year ended December 31, 2013 Net revenues from discontinued operations $ 268,892 $ 311,596 Cost of goods sold (26,798) (11,835) Selling expenses (6,525) (11,515) Royalties 13,433 4,158 Other income from discontinued operations $ 249,002 $ 284,088 December 31, 2014 December 31, 2013 Assets Accounts Receivable, net $ 46,845 $ 21,391 Inventories - 26,798 Total assets of discontinued operations $ 46,845 $ 48,189

Cash (Details)

Cash (Details)	Dec. 31, 2014USD ($)
Cash Details
Other assets include restricted cash	$ 10,000

Restricted Cash (Details)

Restricted Cash (Details)	Dec. 31, 2014USD ($)
Restricted Cash Details
Other non-current asset certificate of deposit	$ 10,000
Annual interest rate	0.60%

Going Concern (Details)

Going Concern (Details)	Dec. 31, 2014USD ($)
Going Concern Details
Accumulated deficit (approx)	$ 2,624,000
Working capital deficit (approx)	$ 188,000

Equipment (Details)

Equipment (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Equipment Consists Of the Following:
Computer Hardware	$ 10,747	$ 10,747
Office Furniture and Equipment	3,639	3,639
Shipping and Other Equipment	1,575	1,575
Molding Equipment Interests	0	90,000
Total Equipment	15,961	105,961
Accumulated Depreciation	(15,961)	(36,828)
Property and equipment, net	$ 0	$ 69,133

Equipment - Depreciation (Detai

Equipment - Depreciation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Equipment - Depreciation Details
Depreciation expense	$ 21,133	$ 23,320

License (Details)

License (Details)	Dec. 31, 2012
License Agreements Consists Of the Following:
New License Agreement for an exclusive worldwide license with a royalty on net sales percent	30.00%

Intangible Asset (Details)

Intangible Asset (Details) - USD ($)	Dec. 31, 2014	Dec. 09, 2014
Intangible Asset Details
Issued shares for the rights, title and interest		100,000,000
Fair value of the shares of common stock recorded as intangible assets	$ 210,000
Impairment of intangible assets	$ 210,000

Capital Stock Transactions (Det

Capital Stock Transactions (Details)	Dec. 31, 2014$ / sharesshares
PREFERRED STOCK:
Preferred Stock, shares authorized | shares	5,000,000
Preferred Stock, par value | $ / shares	$ 0.001
COMMON STOCK:
Common Stock shares authorized | shares	699,999,999
Common Stock, par value | $ / shares	$ 0.001
Voting rights	50.00%

Capital Stock Transactions Duri

Capital Stock Transactions During 2013 (Details) - $ / shares	Nov. 15, 2013	Jul. 15, 2013	Jul. 10, 2013
Capital Stock Transactions During 2013 Details
Shares of common stock issued for legal services			2,000,000
Shares of common stock issued for legal services, per share			$ 0.006
Shares of common stock issued for consulting services	5,000,000	4,000,000
Shares of common stock issued for consulting services, per share	$ 0.005	$ 0.006

Capital Stock Transactions Du32

Capital Stock Transactions During 2014 (Details) - $ / shares	Dec. 09, 2014	Sep. 30, 2014	Jun. 19, 2014	Mar. 31, 2014
Capital Stock Transactions During 2014 Details
Issued shares of common stock for consulting services				2,500,000
Issued shares of common stockfor consulting services per share				$ 0.0035
Issued shares of common stock for consulting services				2,500,000
Issued shares of common stockfor consulting services per share				$ 0.004
Issued shares of common stock for consulting services				2,000,000
Issued shares of common stockfor consulting services per share				$ 0.0035
Issued shares of common stock for legal services				5,000,000
Issued shares of common stock for legal services per share				$ 0.006
Issued shares of common stock for a conversion of notes payable for accrued wages		26,562,500	45,000,000
Issued shares of common stock for a conversion of notes payable for accrued wages per share		$ 0.002	$ 0.003
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages		21,476,435	45,000,000
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages per share		$ 0.002	$ 0.003
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages		26,562,500
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages per share		$ 0.002
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages		21,250,000
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages per share		$ 0.002
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages		7,682,165
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages per share		$ 0.002
Issued shares of common stockin regard to a Material Definitive Agreement	100,000,000
Issued shares of common stockin regard to a Material Definitive Agreement per share	$ 0.0035

Capital Stock Transactions Du33

Capital Stock Transactions During 2015 (Details) - $ / shares	Nov. 30, 2015	Nov. 17, 2015	Nov. 16, 2015	Nov. 09, 2015	Aug. 31, 2015	Jun. 08, 2015	Jun. 01, 2015	Apr. 17, 2015	Apr. 11, 2015	Apr. 01, 2015
Capital Stock Transactions During 2015
Shares of common stock for consulting services	5,000,000	31,500,000					3,000,000		2,000,000	10,000,000
Shares of common stock for consulting services per share	$ 0.0025	$ 0.0025					$ 0.0025		$ 0.0025	$ 0.0025
Shares of common stock for Private Placement		4,000,000	2,000,000	3,000,000	10,000,000	1,000,000		20,000,000	20,000,000
Shares of common stock for Private Placement per share		$ 0.0025	$ 0.0025	$ 0.0025	$ 0.0025	$ 0.0025		$ 0.0025	$ 0.0025
Shares of common stock for legal services	2,500,000						7,000,000
Shares of common stock for legal services per share	$ 0.0025						$ 0.0025
Shares of common stock issued		20,000,000
Shares of common stock, valued at per share		$ 0.0025

Capital Stock Transactions Du34

Capital Stock Transactions During 2016 (Details) - $ / shares	May 31, 2016	May 26, 2016	May 02, 2016	Mar. 21, 2016	Mar. 07, 2016	Feb. 26, 2016	Feb. 22, 2016	Feb. 05, 2016	Feb. 01, 2016	Jan. 22, 2016	Jan. 04, 2016
Capital Stock Transactions During 2016
Issued shares of common stock for consulting services		2,500,000	1,000,000		10,000,000				2,500,000	2,500,000	2,500,000
Issued shares of common stockfor consulting services per share		$ 0.0066	$ 0.0025		$ 0.0025				$ 0.0025	$ 0.0025	$ 0.0025
Issued shares of common stock for for an investment in Private Placement		2,000,000	1,000,000	100,000,000		1,000,000		8,000,000
Issued shares of common stock for an investment in Private Placement per share		$ 0.0025	$ 0.0025	$ 0.0025		$ 0.0025		$ 0.0025
Issued shares of common stock in regard to a License Agreement							5,451,000
Issued shares of common stock in regard to a License Agreement per share							$ 0.0030
Issued shares of common stock for legal services	2,500,000
Issued shares of common stockfor legal services per share	$ 0.0066

Summary of warrants outstanding

Summary of warrants outstanding (Details)	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2013USD ($)$ / sharesshares
Shares:
Exercisable shares	0	250,000
Granted	0	0
Exercised	0	0
Weighted- Average Exercise Price | $ / shares	$ 0	$ 1
Weighted- Average Remaining Contractual Term	0	0.25
Aggregate Intrinsic Value | $	$ 0	$ 0

Related Party Transactions Agre

Related Party Transactions Agreement (Details) - USD ($)	Dec. 31, 2014	Sep. 30, 2014	Jun. 19, 2014	Dec. 31, 2013
Related Party Transactions Agreement:
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages		26,562,500	45,000,000
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages per share		$ 0.002	$ 0.003
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages		21,476,435	45,000,000
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages per share		$ 0.002	$ 0.003
Shares of common stock to an officer for a conversion of notes payable for accrued wages		26,562,500
Shares of common stock to an officer for a conversion of notes payable for accrued wages valued at per share		$ 0.002
Shares of common stock to an officer for a conversion of notes payable for accrued wages		21,250,000
Shares of common stock to an officer for a conversion of notes payable for accrued wages valued at per share		$ 0.002
Shares of common stock to an officer for a conversion of notes payable for accrued wages		7,682,165
Shares of common stock to an officer for a conversion of notes payable for accrued wages valued at per share		$ 0.002
Advanced to the officers	$ 127,000
Accrued officers salary	$ 20,384			$ 43,675

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Income Taxes Narrative Details
Net operating losses carried forward	$ 2,043,048	$ 1,620,213

Income tax expense as reported

Income tax expense as reported is as follows (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income tax expense as reported is as follows details
Net loss before income taxes per financial statements	$ (288,750)	$ (551,658)
Income tax rate	45.00%	45.00%
Income tax recovery	$ (123,619)	$ (248,246)
Permanent differences	6,318	155,499
Change in valuation allowance	117,301	92,747
Provision for income taxes	$ 0	$ 0

Components of deferred income t

Components of deferred income tax assets and liabilities (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Components of deferred income tax assets and liabilities:
Net operating loss carry-forward	$ 846,397	$ 729,096
Valuation allowance	(846,397)	(729,096)
Net deferred income tax asset	$ 0	$ 0

Results of discontinued operati

Results of discontinued operations (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Results of discontinued operations details
Net international revenues	$ 268,892	$ 311,596
Cost of goods sold	(26,798)	(11,835)
Selling expense	(6,525)	(11,515)
Royalties	13,433	4,158
Other income from discontinued operations	249,002	284,088
Assets discontinued operations
Accounts Receivable, net	46,845	21,391
Inventories	0	26,798
Total assets of discontinued operations	$ 46,845	$ 48,189

Subsequent Events During 2015 (

Subsequent Events During 2015 (Details) - $ / shares	Nov. 30, 2015	Nov. 17, 2015	Nov. 16, 2015	Nov. 09, 2015	Aug. 31, 2015	Jun. 08, 2015	Jun. 01, 2015	Apr. 17, 2015	Apr. 11, 2015	Apr. 01, 2015
Subsequent Events During 2015 Details
Shares of common stock for consulting services	5,000,000	31,500,000					3,000,000		2,000,000	10,000,000
Shares of common stock for consulting services per share	$ 0.0025	$ 0.0025					$ 0.0025		$ 0.0025	$ 0.0025
Shares of common stock for Private Placement		4,000,000	2,000,000	3,000,000	10,000,000	1,000,000		20,000,000	20,000,000
Shares of common stock for Private Placement per share		$ 0.0025	$ 0.0025	$ 0.0025	$ 0.0025	$ 0.0025		$ 0.0025	$ 0.0025
Shares of common stock for legal services	2,500,000						7,000,000
Shares of common stock for legal services per share	$ 0.0025						$ 0.0025
Shares of common stock for Private Placement		20,000,000
Shares of common stock for Private Placement per share		$ 0.0025

Subsequent Events During 2016 (

Subsequent Events During 2016 (Details) - $ / shares	May 31, 2016	May 26, 2016	May 03, 2016	May 02, 2016	Mar. 21, 2016	Mar. 07, 2016	Feb. 26, 2016	Feb. 22, 2016	Feb. 05, 2016	Feb. 01, 2016	Jan. 22, 2016	Jan. 04, 2016
Subsequent Events During 2016
Issued shares of common stock for consulting services		2,500,000		1,000,000	100,000,000	10,000,000				2,500,000	2,500,000	2,500,000
Issued shares of common stockfor consulting services per share		$ 0.0025		$ 0.0025	$ 0.0025	$ 0.0025				$ 0.0025	$ 0.0025	$ 0.0025
Issued shares of common stock for for an investment in Private Placement		2,000,000		1,000,000			1,000,000		8,000,000
Issued shares of common stock for an investment in Private Placement per share		$ 0.0025		$ 0.0025			$ 0.0025		$ 0.0025
Issued shares of common stock in regard to a License Agreement								5,451,000
Issued shares of common stock in regard to a License Agreement per share								$ 0.0030
Common shares of holdings in MolecuVax, Inc. retired to treasury				62,500,000
Common shares currently owned in MolecuVax, Inc.				37,500,000
Common shares issued in conjunction with a licensing agreement between MVAX and UNIVAX, LLC.			37,500,000
Issued shares of common stock for legal services	2,000,000
Issued shares of common stockfor legal services per share	$ 0.0066